Custom CRISPR sgRNA Adenovirus
abm’s Custom CRISPR sgRNA vectors and viruses are your high quality choice for harnessing the power of CRISPR Cas9 gene editing with a wide range of expression systems. Whether you need sgRNA expression for knockouts, knock-ins, activation, or repression, abm has you covered. Just tell our dedicated and highly experienced team what you want to accomplish, and we’ll do the sgRNA design, cloning, and adenoviral packaging for you!
Adenovirus is a popular choice for in vivo (and in vitro) applications due to its advantages: low immunogenicity for high post-infection cell viability, broad host range (dividing/nondividing cells) and high infection efficiency without integration into host DNA, making it ideal for gene editing or regulation with minimal off-target effects.
Testimonial:
“Construct works beautifully, definitely will get more if needed.”
Emily Chen, UCLA, CRISPR Constructs
Additional Resources:
Service Details
| SERVICE NAME | SIZE | TITER | CAT. NO. |
|---|---|---|---|
| Custom CRISPR sgRNA Adenovirus (for spCas9) – single target | 1 ml | 106 pfu/ml | C446 |
Additional Services
| SERVICE NAME | SIZE | TITER | CAT. NO. |
|---|---|---|---|
| Recombinant Adenovirus Amplification | 2-3 ml | 109 pfu/ml | C070 |
| Recombinant Adenovirus Amplification | 2-3 ml | 1010 pfu/ml | C071 |
| Recombinant Adenovirus Amplification | 5 x 200 ul | 1011 pfu/ml | C072 |
| Recombinant Adenovirus Amplification | 5 x 200 ul | 1012 pfu/ml | C005 |
| Plaque Purification using ABMC1 cells | 1 service | C005 | |
| Plaque Assay for adenovirus titer | 1 service | C006 | |
| RCA Assay using A549 cells | 1 service | C007 | |
| TCID50 Assay using 293 cells | 1 service | C008 | |
| 293 Cell Line – low passages for viral production | Single Clone | C009 | |
| ABMC1 Cell Line – for plaque assay E1-expressing Retinoblastoma Cells | Single Clone | C010 |
The viral titer will be calculated by end-point dilution assay by default. abm cannot guarantee resolution of titer discrepancies involving any other quantification methods.
The vector for our CRISPR sgRNA Adenoviruses is pAdeno-sgRNA. abm’s adenoviruses are replication-incompetent (-E1/-E3) and based on human adenovirus type 5 (Ad5).
Additional Info
| SERVICE NAME | AAV VECTOR /VIRUS |
LENTIVECTOR /VIRUS |
NON-VIRAL VECTOR |
ADENOVIRUS |
|---|---|---|---|---|
| sgRNA for spCas9 | Available | Available | Available | Available |
| sgRNA for saCas9 | Available | – | – | – |
| All-in-One with spCas9 | – | Available | Available | – |
| All-in-One with saCas9 | Available | – | – | – |
| All-in-One with FnCas12a (FnCpf1) | – | Available | – | – |
| Browse Collection | Browse Collection | Browse Collection | Browse Collection |
Related Products
FAQs
Does your amplification and purification service include any additional titre verification, such as a Plaque Assay, RCA Assay or TCID50 Assay?
The viral titre will be calculated by end-point dilution assay. Any additional assays required (such as those listed above) can be provided on request, at an additional cost.
Do you sell the adenoviral vectors that you have used to make any of your prepackaged adenovirus?
Our adenoviral vectors are currently only available as packaged viral particles. We do offer custom cloning services if further modifications are desirable.
What will be the final composition of your high titer, nonpurified adenovirus?
Our high titer adenoviruses are re-suspended in 50 mM Tris-HCl (pH 7.0) with 5% glycerol
Citations
| 01 | Kang, Y. J. et al. “Regulation of NKT cell-mediated immune responses to tumours and liver inflammation by mitochondrial PGAM5-Drp1 signalling.” Nat. Commun. (2015) 6:8371doi: 10.1038/ncomms9371 |
| 02 | Jiang, G. et al. “Isorhapontigenin (ISO) inhibits invasive bladder cancer (BC) formation in vivo and human BC invasion in vitro by targeting STAT1/FOXO1 Axis.” Cancer Prev Res. Published Online First April 14, 2016.doi: 10.1158/1940-6207.CAPR-15-0338 |
| 03 | Okugawa, Y. et al. “Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer.” Gut (2015)doi:10.1136/gutjnl-2015-309359 |
